Key facts
- This page summarizes Sol Langermann's Form 4 filing for NextCure, Inc. (NXTC).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 03 Feb 2025, 18:22.
Sol Langermann - 31 Jan 2025 Form 4 Insider Report for NextCure, Inc. (NXTC)
- Reporting relationship
- Chief Scientific Officer
- Issuer ticker
- NXTC
- Reported as of
- 31 Jan 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Feb 2025, 18:22:38 UTC
- Prior SEC filing
- 02 Apr 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Steven P. Cobourn, as attorney-in-fact for Sol Langermann
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Sol Langermann filed Form 4 for NextCure, Inc. (NXTC) on 03 Feb 2025.
Change
- Previous filing in this sequence was filed on 02 Apr 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NXTC
transaction
Derivative
Employee Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +117,375
- Change %
- Price
- $0.000000
- Shares after
- 117,375
- Date
- 31 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 117,375
- Exercise price
- $0.8048
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
One fourth of the option vests on January 31, 2026. The remainder vests in 36 monthly installments beginning on February 28, 2026.